EGFR and non-small cell lung carcinoma: The use of first-generation EGFR TKIs like erlotinib and gefitinib in the second-line treatment of patients with EGFR-mutant NSCLC is supported by prospective single-arm studies, retrospective biomarker analyses of phase-II studies and subgroup analyses from phase-III studies (11–20).